Stocks · News reference
Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13
Goldman Sachs analyst Salveen Richter maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $11 to $13.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform rating.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies granted five new employees 314,000 RSUs and options to purchase 92,400 shares as inducement for employment. The RSUs vest over four years, while stock options have a $5.70 exercise price and 10-year term with four-year vesting schedule.
Taysha Gene Therapies shares are trading lower after the company reported worse-than-expected Q2 EPS results.